Journal ArticleDOI
Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
Sylvie Giacchetti,Anne-Sophie Hamy,Suzette Delaloge,Etienne Brain,Frédérique Berger,Brigitte Sigal-Zafrani,Marie-Christine Mathieu,Philippe Bertheau,Jean Marc Guinebretière,Mahasti Saghatchian,Florence Lerebours,chafouny mazouni,O Tembo,Marc Espié,Fabien Reyal,Michel Marty,Bernard Asselain,Jean-Yves Pierga +17 more
Reads0
Chats0
TLDR
Celecoxib combined with NAC provided neither pCR nor survival benefit in patients with HER2-negative BC, suggesting that Axillary pCR could be a more relevant surrogate of survival than in the breast in HER1-positive population.About:
This article is published in European Journal of Cancer.The article was published on 2017-04-01. It has received 23 citations till now. The article focuses on the topics: Trastuzumab & Population.read more
Citations
More filters
Journal ArticleDOI
Development and Clinical Application of anti-HER2 Monoclonal and Bispecific Antibodies for Cancer Treatment
TL;DR: The recent advancement of HER2-targeted monoclonal antibodies and bispecific antibodies (MM-111, ertumaxomab and HER2Bi-aATC) are summarized, especially focus on clinical trial results.
Journal ArticleDOI
Celecoxib in breast cancer prevention and therapy.
Jieqing Li,Qiongyu Hao,Wei Cao,Wei Cao,Jaydutt V. Vadgama,Jaydutt V. Vadgama,Yong Wu,Yong Wu +7 more
TL;DR: Different mechanisms of anticancer effect of celecoxib are discussed as well as preclinical/clinical results signifying this beneficial effect.
Journal ArticleDOI
Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages
Qi Chen,Jianxin Wang,Qi Zhang,Jingying Zhang,Yu Lou,Jiaqi Yang,Yiwen Chen,Tao Wei,Jian Zhang,Qihan Fu,Mao Ye,Xiaozhen Zhang,Xiaowei Dang,Tingbo Liang,Xueli Bai +14 more
TL;DR: A pro-inflammatory mechanism in PDAC was revealed, which indicated that IL-1β and COX-2 could be therapeutic targets of an anti-inflammatory strategy to treat PDAC.
Journal ArticleDOI
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial
Anne-Sophie Hamy,Sandrine Tury,Xiaofei Wang,Junheng Gao,Jean-Yves Pierga,Sylvie Giacchetti,E. Brain,Barbara Pistilli,Michel Marty,Marc Espié,Gabriel Benchimol,Enora Laas,Marick Laé,Bernard Asselain,Brice Aouchiche,Martin J. Edelman,F Reyal +16 more
TL;DR: Celecoxib use during chemotherapy adversely affected survival in patients with breast cancer, and the effect was more marked in PTGS2-low and/or estrogen receptor-negative tumors, and COX-2 inhibitors should preferably be avoided during docetaxel use in patientswith breast cancer who are undergoing NAC.
Journal ArticleDOI
Silencing COX-2 blocks PDK1/TRAF4-induced AKT activation to inhibit fibrogenesis during skeletal muscle atrophy.
Hongtao Chen,Zhanyang Qian,Sheng Zhang,Tang Jian,Le Fang,Fan Jiang,Dawei Ge,Jie Chang,Jiang Cao,Lei Yang,Xiaojian Cao +10 more
TL;DR: In vivo pharmacological inhibition of COX-2 by celecoxib decreased tissue fibrosis and increased skeletal muscle fiber preservation reflected by less ECM formation and myofibroblast accumulation with decreased p-ERK1/2, p-Smad2/3, TGF-βR1, VEGF, NOX2 and NOX4 expression.
References
More filters
Journal ArticleDOI
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar,Lijun Zhang,Michael Untch,Keyur Mehta,Joseph P. Costantino,Norman Wolmark,Hervé Bonnefoi,David Cameron,Luca Gianni,Pinuccia Valagussa,Sandra M. Swain,Tatiana M. Prowell,Sibylle Loibl,D. Lawrence Wickerham,Jan Bogaerts,José Baselga,Charles M. Perou,Gideon M. Blumenthal,Jens Uwe Blohmer,Eleftherios P. Mamounas,Jonas Bergh,Vladimir Semiglazov,Robert Justice,Holger Eidtmann,Soonmyung Paik,Martine Piccart,Rajeshwari Sridhara,Peter A. Fasching,Leen Slaets,Shenghui Tang,Bernd Gerber,Charles E. Geyer,Richard Pazdur,Nina Ditsch,Priya Rastogi,Wolfgang Eiermann,Gunter von Minckwitz +36 more
TL;DR: In this paper, the authors compared the three most commonly used definitions of pathological complete response (ypT0 ypN0, ypT0/is ypNs0, and ypTsN0/IsYPN0) for their association with EFS and overall survival in clinical trials of neoadjuvant treatment of breast cancer.
Journal ArticleDOI
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Elżbieta Senkus,Stella Kyriakides,Frédérique Penault-Llorca,P.M. Poortmans,Alexander J. Thompson,Sophia Zackrisson,Fatima Cardoso +6 more
TL;DR: This work presents the results of a meta-analysis conducted at the 2016 European Oncology and Radiotherapy Guidelines Working Group (ESMO) workshop on breast cancer diagnosis and prognosis of women with atypical central giant cell granuloma (CGM) who have previously had surgery.
Journal ArticleDOI
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz,Michael Untch,Jens-Uwe Blohmer,SD Costa,Holger Eidtmann,Peter A. Fasching,Bernd Gerber,Wolfgang Eiermann,Jörn Hilfrich,Jens Huober,Christian Jackisch,Manfred Kaufmann,Gottfried E. Konecny,Carsten Denkert,Valentina Nekljudova,Keyur Mehta,Sibylle Loibl +16 more
TL;DR: The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain this paper, however, it is known that pCR is associated with long-term outcome of 6,377 patients with primary breast cancer receiving neoadjuvant anthracycline-taxane-based chemotherapy in seven randomized trials.
Journal ArticleDOI
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni,Tadeusz Pienkowski,Young Hyuck Im,L Roman,Ling Ming Tseng,Mei Ching Liu,Ana Lluch,Elżbieta Starosławska,Juan de la Haba-Rodriguez,Seock-Ah Im,Jose Luiz Pedrini,Brigitte Poirier,Paolo Morandi,Vladimir Semiglazov,Vichien Srimuninnimit,Giulia Bianchi,Tania Szado,Jayantha Ratnayake,Graham Ross,Pinuccia Valagussa +19 more
TL;DR: Pertuzumab and trastuzumAB without chemotherapy eradicated tumours in a proportion of women and showed a favourable safety profile, which justifies further exploration in adjuvant trials and support the neoadjuvant approach for accelerating drug assessment in early breast cancer.
Journal ArticleDOI
Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi,Stewart J. Anderson,Harry D. Bear,Charles E. Geyer,Morton S. Kahlenberg,André Robidoux,Richard G. Margolese,James L. Hoehn,Victor G. Vogel,Shaker R. Dakhil,Deimante Tamkus,Karen M. King,Eduardo R. Pajon,Mary Johanna Wright,Jean Robert,Soonmyung Paik,Eleftherios P. Mamounas,Norman Wolmark +17 more
TL;DR: B-18 and B-27 demonstrate that preoperative therapy is equivalent to adjuvant therapy and showed that the addition of preoperative taxanes to AC improves response.